Loading...
BioMark Diagnostics Inc.
BUX.CN•CNQ
HealthcareMedical - Diagnostics & Research
$0.28
$0.00(0.00%)
BioMark Diagnostics Inc. (BUX.CN) Stock Overview
Explore BioMark Diagnostics Inc.’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for BUX.CNStats details for BUX.CN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for BUX.CNAnalyst Recommendations details for BUX.CN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.
CEO
Mr. Rashid Ahmed Maula Bux B.Sc., MBA
Headquarters
3851 Shell Road, Richmond, BC
Founded
2014